Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study

Figures & data

Table 1 Demographic and laboratory characteristics of enrolled subjects

Characteristic	Total patients (n=1,280)
Age (years) mean ±SD	52.62±7.974
Sex, n (%) Male; female	1,100 (85.9%); 180 (14.1%)
Pre-treatment status, n (%) Naïve; experienced	940 (73.4%); 340 (26.6%)
Fibrosis score by Fibroscan, n (%) F1;F2;F3; F4	90 (7%); 430 (33.6%); 290 (22.7%); 470 (36.7%)
Liver status (Child–Pugh score), n (%) Non-cirrhotic; A; B	520 (40.6%); 370 (28.9); 390 (30.5%)
Pre-treatment prothrombin time (seconds), n (%) Normal; <4 seconds; >4 seconds	570 (44.5%); 340 (26.6%); 370 (28.9%)
Pre-treatment ALT level, n (%) Normal; raised	350 (27.3%); 930 (72.7%)
Pre-treatment serum bilirubin level, n (%) Normal; raised	690 (53.9%); 590 (46.1%)
Pre-treatment serum albumin level (g/dL), mean ± SD	3.662±0.5
Pre-treatment serum bilirubin level (mg/dL), mean ± SD	1.329±0.6

Table 2 Univariate analysis of factors associated with the presence of OCI

Characteristics	Negative OCI (n= 1,230)	Positive OCI (n=50)	P-value
Age, mean ± SD	52.89±8.020	46.00±0	0.012a
Sex, n (%) male female	1,050 (85.4%)	50 (100%)	0.463b
	180 (14.6%)	0 (0%)
Pre-treatment status, n (%)			0.001b
Naive	940 (76.4%)	0 (0%)
Experienced (INF therapy)	290 (23.6%	50 (100%)
Fibroscan score, n (%)			0.149b
FI	90 (7.3%)	0 (0%)
F2	430 (35.0%)	0 (0%)
F3	260 (21.1%)	34 (68%)
F4	450 (36.6%)	16 (32%)
Child-Pugh score, n (%)			0.148b
None cirrhotic	520 (42.3%)	0 (0%)
A	350 (28.5%)	30 (60%)
B	360 (29.3%)	20 (40%)
Pre-treatment ALT, n (%)			0.196b
Normal	350 (28.5%)	11 (22%)
Raised	880 (71.5%)	39 (78%)
Post-treatment ALT, n (%)			0.012b
Normalized	1,200 (97.6%)	42 (84%)
Not normalized	30 (2.4%)	8 (16%)
Pre-treatment prothrombin time (seconds), n (%)			0.018b
Normal	570 (46.3%)	3 (6%)
<4 seconds	300 (24.4%)	33 (66%)
>4 seconds	360 (29.3%)	14 (28%)
Post-treatment prothrombin time (seconds), n (%)			0.001
Normal	630 (51.2%)	0 (0%)
<4 seconds	300 (24.4%)	36 (72%)
>4 seconds	300 (24.3%)	14 (28%)
Pre-treatment bilirubin level (mg/dL), mean ± SD	1.354±.6575	0.720±.0837	0.0001a
Post-treatment bilirubin level (mg/dL), mean ± SD	0.9±0.04	1 ±007	0.3441
Pre-treatment albumin level (g/dL), mean ± SD	3.637±.5009	4.280±.1789	0.001a
Post-treatment albumin level (g/dL), mean ± SD	3.9±0.4	4±0.5	0.132
Pre-treatment viral load (logm RNA by IU/mL), mean ± SD	5.4±2	4.9±1	0.24

Notes:

a t-Test.

b Chi-squared test.

Abbreviations: ALT, alanine aminotransferase; INF, interferon; OCI, occult C infection.

Table 3 Logistic regression analysis for potential risk factors for the existence of OCI Variable B SE Wald df Sig. Odds ratio

Pre-treatment viral load (reference group; <100,000) *>800,000	3.334	1.120	8.854	1	0.003	7.03
Pre-treatment ALT level (reference group; normal) *increased	7.79	60.45	0.017	1	0.02	5.13
Fibroscan (reference group; F0) *F4	2.56	0.989	6.89	1	0.009	4.43
Pre-treatment prothrombin level (reference group; normal) *4–6 seconds	2.04	0.97	4.423	1	0.035	2.684
Pre-treatment albumin level (reference group; normal) *raised.	1.709	0.984	3.12	1	0.008	2.522
Child score (reference; non cirrhotic) *Child B	1.69	1.43	1.39	1	0.23	1.91
Treatment status (reference group; naive) * treatment experienced	1.62	0.894	3.304	1	0.06	1.5
Pre-treatment bilirubin level (reference group; normal) * raised	0.79	0.95	0.69	1	0.406	1.20
Constant	–3.17	1.943	2.66	1	0.01	0.42

Note:

* the potential risk factor (predictor).

Abbreviations: ALT, alanine aminotransferase; OCI, occult C infection.